Participant Enrolled in Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

As of April 15, 2022, the second and third participants are screening for treatment in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) Medical Center in Bronx, New York. The study is expected to treat up to 60 participants over 2-3 years.

This Phase 2, open-label randomized controlled comparative study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD is led by PTSD researcher Rachel Yehuda, Ph.D., Director at the Mental Health Patient Care Center, James J. Peters VA Medical Center, and Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai Hospital. The study is a part of the investigator-initiated research program of the U.S. Department of Veterans Affairs (VA).